BRITISH COLUMBIA | Ministry of Health

SPECIAL AUTHORITY REQUEST

TARGETED THERAPIES FOR CROHN'S DISEASE

HLTH 5368 Rev. 2025/02/06

INITIAL/SWITCH COVERAGE

For up-to-date criteria and forms, please check: www.gov.bc.ca/pharmacarespecialauthority

Fax requests to 1-800-609-4884 (toll free) OR mail requests to: PharmaCare, Box 9652 Stn Prov Govt, Victoria, BC V8W 9P4
This facsimile is doctor-patient privileged and contains confidential information intended only for PharmaCare. Any other distribution, copying or disclosure is strictly prohibited.

If PharmaCare approves this Special Authority request, approval is granted solely for the purpose of covering prescription costs. PharmaCare approval does not indicate that the requested medication is, or is not, suitable for any specific patient or condition.

If you have received this fax in error, please write MISDIRECTED across the front of the form and fax toll-free to 1-800-609-4884, then destroy the pages received in error.

Forms with information missing will be returned for completion. If no prescriber fax or mailing address is provided, PharmaCare will be unable to return a response.

SECTION 1 – PRESCRIBING GASTROENTEROLOGIST'S INFO.

Name and Mailing Address	
College ID (use ONLY College ID number)	Phone Number (include area code)
CRITICAL FOR A TIMELY RESPONSE → Prescriber's Fax Number	

SECTION 2 – PATIENT INFORMATION

Patient (Family) Name	
Patient (Given) Name(s)	
Date of Birth (YYYY / MM / DD)	Date of Application (YYYY / MM / DD)
CRITICAL FOR PROCESSING → Personal Health Number (PHN)	

SECTION 3 – MEDICATION REQUESTED

◯ **ADALIMUMAB:** Abrilada®, Amgevita®, Hadlima®, Hulio®, Hyrimoz®, Idacio®, Simlandi™, Yuflyma®
12 week supply: 160 mg SC week 0, 80 mg SC week 2, then 40 mg SC weeks 4, 6, 8, and 10

◯ **INFLIXIMAB:** Avsola®, Inflectra®, Remsima™ SC, Renflexis®
◯ **3 doses:** 5 mg/kg IV at 0, 2, and 6 weeks
◯ **12 weeks:** 5 mg/kg IV at 0, 2, and 6 weeks, plus 120 mg SC at weeks 10 and 12

◯ **RISANKIZUMAB:** **16 week supply:** 600 mg IV at 0, 4, and 8 weeks, then 360 mg SC at week 12

◯ **UPADACITINIB:** **16 week supply:** 45 mg PO once daily for 12 weeks, then 15 to 30 mg PO once daily

◯ **USTEKINUMAB:** Steqeyma®, Wezlana™
12 week supply:
≤55 kg: 260 mg IV as a single dose, then 90 mg SC every 8 weeks thereafter
>55-≤85 kg: 390 mg IV as a single dose, then 90 mg SC every 8 weeks thereafter
>85 kg: 520 mg IV as a single dose, then 90 mg SC every 8 weeks thereafter

◯ **VEDOLIZUMAB:** ◯ **3 doses:** 300 mg IV at 0, 2, and 6 weeks
◯ **12 weeks:** 300 mg IV at 0, 2, and 6 weeks, plus 108 mg SC at weeks 8, 10, and 12

SECTION 4 – PRE-TREATMENT CLINICAL INFORMATION

Diagnosis ◯ Moderate to Severe Active Crohn's ◯ Active Fistulizing Crohn's	Year of Crohn's Diagnosis	Current Weight in Kg
Current Steroid Dose	Impact of Current Condition on Work/Social Life ◯ None ◯ Mild ◯ Moderate ◯ Severe	

FOR MODERATE TO SEVERE CROHN'S

Site of Crohn's ◯ Isolated Colonic ◯ Ileal Colonic ◯ Small Bowel ◯ Other (specify)	Current **Harvey Bradshaw Index** (Hbi ≥ 8)

FOR ACTIVELY FISTULIZING CROHN'S

Site of Fistula(e) ◯ Perianal ◯ Enterocutaneous ◯ Recto-Vaginal ◯ Other (specify)	Number of Fistulae
Fistula Drainage and Bleeding: ◯ None ◯ Mild ◯ Moderate ◯ Severe	Pain at Fistula Sites: ◯ None ◯ Mild ◯ Moderate ◯ Severe

For consideration of off-criteria requests, additional information demonstrating moderate to severe active disease should be submitted. If approved, an equivalent assessment is required within 9 months of starting treatment to demonstrate medication efficacy. Patient information enclosed:
☐ Colonoscopy ☐ Fecal Calprotectin Level ☐ Other (specify) _____

PHARMACARE USE ONLY

Continued on page 2 >>

Status	Effective Date (YYYY / MM / DD)	Duration of Approval

PATIENT NAME	PHN	DATE (YYYY / MM / DD)

SECTION 5 – CONCURRENT THERAPY

INCLUDE ALL antidiarrheals, narcotics, immunosuppressants, antibiotics

	DRUG, DOSE/ROUTE, FREQUENCY
1	
2	
3	

SECTION 6 – PRIOR THERAPIES (INITIAL COVERAGE)

FOR PATIENTS WITH MODERATE TO SEVERE ACTIVE CROHNS - DETAILS OF GLUCOCORTICOID TRIAL (REQUIRED)

◯ **Patient has had a course of steroids equivalent to oral prednisone 40 mg or more daily for a minimum of 14 days.**

- ◯ Patient is steroid **resistant**, displaying a lack of a **symptomatic response** to therapy.
- ◯ Patient is steroid **dependent**, unable to withdraw oral corticosteroid within 3 months of initiation without a recurrence of symptoms; a symptomatic relapse within 3 months of stopping; or the need for two or more courses of corticosteroids within one year.

OR

◯ **Patient is unable to complete a course of steroids equivalent to oral prednisone 40 mg or more daily for a minimum of 14 days.**

- ◯ Corticosteroid use is contraindicated (specify): _____
- ◯ Intolerances/side effect(s) (specify): _____

FOR PATIENTS WITH FISTULIZING CROHNS

Drug Name, Dose, Duration (required)	Details of Outcome (Failure, Contraindication, Intolerance, Other)
☐ **Ciprofloxacin** at maximally tolerated doses (min 3 week trial), with/without ☐ **Metronidazole** at maximally tolerated doses (min 3 week trial)	◯ Lack of Effect ◯ Contraindication ◯ Intolerance ◯ Other Specify:

FOR PATIENTS WITH MODERATE TO SEVERE ACTIVE CROHNS AND/OR FISTULIZING CROHNS
SURGICAL HISTORY AND PRIOR MEDICATION USE

MEDICATION	STARTING DATE	DURATION OF USE	OUTCOME (specify intolerances, primary/secondary failures)

PRIOR SURGERIES

☐ None ☐ Ostomy* ☐ Pouch* ☐ Prior resections*

**Please include patient's normal number of liquid bowel movements and HBI worksheet with each coverage request*

SECTION 7 – ADDITIONAL INFORMATION, IF APPLICABLE

SECTION 8 – PRESCRIBER SIGNATURE

Personal information on this form is collected under the authority of, and in accordance with, the *British Columbia Pharmaceutical Services Act* 22(1) and *Freedom of Information and Protection of Privacy Act* 26 (a),(c),(e). The information is being collected for the purposes of (a) administering the PharmaCare program, (b) analyzing, planning and evaluating the Special Authority and other Ministry programs and (c) to manage and plan for the health system generally. If you have any questions about the collection of this information, call Health Insurance BC from Vancouver at 1-604-683-7151 or from elsewhere in BC toll free at 1-800-663-7100 and ask to consult a pharmacist concerning the Special Authority process.

I have discussed with the patient that the purpose of releasing their information to PharmaCare is to obtain Special Authority for prescription coverage and for the purposes set out here.

Prescriber's Signature (Mandatory)

PharmaCare may request additional documentation to support this Special Authority request. Actual reimbursement is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement, and to any other applicable PharmaCare pricing policy.

Save Print Clear Form